Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Effect of the topical application of an ethanol extract of quince seeds on the development of atopic dermatitis-like symptoms in NC/Nga mice

BMC Complementary and Alternative Medicine volume 17, Article number: 80 (2017) Cite this article

Abstract

Background

Quince (Cydonia oblonga Miller) is a deciduous shrub belonging to the Rosaceae family. Quince seed extract has long been used as a cosmetic ingredient for its moisturizing effect. However, little is known about whether quince seed extract has therapeutic effects on keratinocyte-associated skin inflammation.

Methods

In the present study, we investigated the effect of the topical application of ethanol extract of quince seeds (QSEtE) on atopic dermatitis (AD) symptoms in NC/Nga mice. The direct effect of QSEtE on keratinocytes was evaluated using the human keratinocyte cell line HaCaT.

Results

The preliminary application of QSEtE markedly reduced house dust mite allergen-induced skin lesions. The expression of thymus- and activation-regulated chemokine (TARC) in dorsal skin was downregulated. QSEtE directly suppressed the expression and production of TARC in HaCaT cells.

Conclusions

The results suggest that the topical application of QSEtE is effective in preventing the onset of and ameliorating the atopic symptoms of keratinocyte-associated skin inflammation by suppressing TARC production in keratinocytes.

Peer Review reports

Background

Quince (Cydonia oblonga Miller) is a deciduous shrub that belongs to the Rosaceae family and has been mainly cultivated in Asia and areas of the Mediterranean since ancient times [1]. Although quince fruit is not edible owing to its hard, tough and fibrous consistency, it has been used in honeydew and liquors for its pleasant aroma [2]. In addition, peculiar mucilage, which is a mixture of cellulose and water-soluble polysaccharides, is obtained from quince seeds by soaking them in water [3]. The mucilage is reported to have proliferation-enhancing effect on skin fibroblasts [4], healing effects on incised wounds [5], and protective effects against dermal toxicity caused by T2-toxin [6]. Therefore, the mucilage from quince seeds has long been used as a cosmetic ingredient, known as “quince seed extract”, to maintain the barrier function of the skin [7]. However, little is known about the physiological effect of quince seed extract on skin keratinocytes, and the associated onset of atopic side effects on the skin.

Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with intense pruritus and a series of exacerbations and remissions [8]. AD is recognized as a type I and type IV complex according to the Coombs and Gell classification system [9]. Both T-helper (Th2) type immunologic reactions and T-cell-mediated delayed hypersensitivity are involved in AD. In addition, it has been recognized that the expression of various inflammatory chemokines produced by keratinocytes plays important roles in the pathogenesis of AD [10].

In the present study, we aimed to evaluate whether quince seeds have a suppressive effect on the incidence and development of allergic inflammation in the skin. For this purpose, an AD model mouse and a human keratinocyte cell line were used.

Methods

Preparation of QSEtE

The fruits of quince ‘Smyrna’ were purchased from the fruit farm in the Minamiminowa-mura area of Nagano, Japan and were formally surveyed and identified at the Laboratory for Postharvest Science and Functional Properties of Fruits and Vegetables. Twenty grams of seeds was separated from the fruits and immersed in 80 mL ethanol. Then, extraction was performed for 1 week at room temperature. The ethanol extract was then filtered using a Buchner funnel with filter paper discs to remove insoluble residues. Then, the extract was dissolved in water after removal of ethanol and lyophilized using an FD-5 N freeze dryer (EYELA) to obtain powdered QSEtE. We re-constituted QSEtE in ethanol at the indicated concentrations and sterilized using a 0.2-μm pore size cellulose acetate membrane filter (Advantec, Tokyo, Japan) before use.

Mice

Specific pathogen-free, female NC/Nga mice, aged 10 weeks, with 19–23 g body weight were purchased from Charles Liver Laboratories Japan, Inc. (Kanagawa, Japan). The animals were housed at 23 ± 3 °C under a 12-h light/dark cycle and acclimatized for 7 days in laboratory condition before experiments. Food and water were provided ad libitum. All animal protocols were approved by the Committee for Animal Experiments of Shinshu University (Matsumoto, Japan).

Induction of dermatitis

A schematic procedure of the topical application of QSEtE to NC/Nga mice is shown in Fig. 1. At the start of the experiment, mice were randomly divided into the following three groups (n = 6 for each group): ethanol-treated group (vehicle), 0.1% (w/v) QSEtE/ethanol-treated group (0.1% QSEtE), and 1.0% (w/v) QSEtE/ethanol-treated group (1.0% QSEtE). The experimental unit is a cage with a single animal. AD-like skin lesions were induced by topical application of Biostir-AD (Biostir, Kobe, Japan), a hydrophilic petrolatum-based ointment-containing extract of house dust mite (Dermatophagoides farinae), according to the manufacturer’s instructions. The hair on the upper dorsal skin and the back of the ears of mice was shaved under isoflurane anaesthesia, and 100 μL of 4% (w/v) sodium dodecyl sulphate was applied to shaved skin for barrier disruption. After 3 h, 100 μL ethanol (vehicle), 0.1% QSEtE in ethanol, or 1.0% QSEtE in ethanol was applied to the area twice a week. Then, the following week, Biostir-AD was applied to the skin area immediately after QSEtE application. The application of the test substrate and Biostir-AD was repeated twice weekly for a further 3 weeks. On day 28 of the experiment, mice were sacrificed by cervical dislocation. Then, the ear and dorsal skin were harvested for histological analyses and analysis of gene expression, respectively. Any clinical signs related to toxicity, such as remarkable loss of body weight, were monitored in all groups of animals throughout the course of experiment.

Fig. 1
figure 1

Experimental design of QSEtE application. To induce AD-like symptoms, Biostir-AD was topically applied to the skin of NC/Nga mice twice weekly for 3 weeks. Mice were either treated with QSEtE dissolved in ethanol (0.1 or 1.0% QSEtE), or ethanol alone (vehicle) twice weekly 1 week prior to the application of Biostir-AD application

Full size image

Evaluation of the severity of skin lesions

The severity of dermatitis was evaluated according to a previously described method [11]. Briefly, the development of erythema haemorrhage, scarring dryness, oedema and excoriation erosion was scored as 0 (none), 1 (mild), 2 (moderate) and 3 (severe). The sum of the individual scores was taken as the dermatitis score.

Histopathological studies

The harvested ear of mice was immediately fixed in 10% (v/v) neutral buffered formalin and left for 48 h. Then, the fixed ear was sliced and embedded in paraffin, sectioned, deparaffinised and rehydrated at the Biopathology Institute Co., Ltd. (Oita, Japan). The processed sections were either subjected to hematoxylin and eosin staining to evaluate oedema, or subjected to toluidine blue staining to evaluate infiltrated mast cells.

Cells

A human keratinocyte cell line, HaCaT, was purchased from Cell Lines Service GmbH (Eppelheim, Germany). HaCaT cells were cultured using high glucose Dulbecco’s modified Eagle’s medium (Wako Pure Chemical Industries, Ltd., Osaka, Japan) supplemented with 10% heat-inactivated foetal bovine serum (Equitech-Bio, Kerrville, TX, USA), 2 M L-glutamine, 100 U/mL penicillin G and 100 μg/mL streptomycin. Cells were passaged using conventional procedures with 0.05% trypsin in a humidified atmosphere of 5% CO2/95% air at 37 °C.

Induction of thymus and activation-regulated chemokine (TARC)

TARC was induced from HaCaT cells according to the method of Sumiyoshi et al. [12]. Briefly, HaCaT cells (2.5 × 105 cells/1 mL/well) were seeded in a 24-well tissue culture plate (Falcon; Corning Incorporated, Corning, NY, USA) and cultured with the aforementioned concentrations of QSEtE for 24 h. The cells were then stimulated with 10 ng/mL human recombinant tumour necrosis factor (TNF)-α (PeproTech, Rocky Hill, NJ, USA) and 10 ng/mL human recombinant interferon (IFN)-γ (PeproTech). After 6 h, the cells were subjected to quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The culture supernatant was collected 24 h after stimulation and stored at −80 °C for enzyme-link immunosorbent assay (ELISA).

qRT-PCR

TARC mRNA expression in HaCaT cells was analysed by qRT-PCR. Total RNA was extracted from cells using TRI reagent (Merck Millipore, Darmstadt, Germany) according to the manufacturer’s protocol. The extracted RNA (1 μg) was reverse transcribed in a thermal cycler (PTC-200; MJ Research, Waltham, MA, USA) with 1 mM dNTP, 2.5 U/μL M-MLV reverse transcriptase (Thermo Fisher Scientific, Roskilde, Denmark) and 10 pmol/μL random primer at 42 °C for 50 min. qRT-PCR was performed using 0.5 μg cDNA with SYBR Premix Ex Taq II (Takara Bio, Otsu, Japan) and 10 pmol/μL primers. The primer sequences for human TARC (GenBank: NM_002987.2) were designed as 5′-TTTGAGCTCACAGTGTCACC-3′ (forward) and 5′-GGAGTCTCTGTGTGCAGGTC-3′ (reverse), and were complementary to 18–37 and 110–91, respectively. The primer sequences for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH; GenBank: AF261085.1) were designed as 5′- CTGCTCCTCCTGTTCGACAG-3′ (forward) and 5′- GCGCCCAATACGACCAAATC-3′ (reverse), and were complementary to 33–52 and 151–132, respectively. PCR comprised 1 cycle of preheating (95 °C, 10 min), 40 cycles of denaturation (95 °C, 10 s), and primer annealing and extension (55 °C, 30 s) using an Eco Real Time PCR System (Illumina, San Diego, CA, USA). Results were analysed with the ΔΔCt method using Eco system software (Illumina). The amounts of PCR products were normalised to the expression level of GAPDH mRNA.

ELISA

IgE level in mice serum and TARC produced by HaCaT cells in culture supernatant were measured using sandwich ELISA. The detailed procedure to measure IgE was described previously [13]. To measure TARC, 50 μL of 2 μg/mL mouse anti-human TARC (R & D Systems, Minneapolis, MN, USA) dissolved in 0.1 M carbonate buffer (pH 10.0) was added to each well of a 96-well Nunc Immuno Plate MaxiSorp (Thermo Fisher Scientific) and incubated at 30 °C for 2 h. Each well was washed three times with phosphate-buffered saline (PBS; pH 7.2) containing 0.05% Tween 20 (PBST) and then post-coated with 300 μL 1% Block Ace (DS Pharma Biomedical, Osaka, Japan) in 0.1 M sodium carbonate buffer (pH 10.0) at 4 °C overnight. After the plates were washed three times with PBST, 50 μL culture supernatant or a standard solution optimally diluted with PBS was added to each well and incubated at 37 °C for 2 h. Recombinant human TARC (Shenandoah Biotechnology, Warwick, PA, USA) was used as the standard. The plates were then washed 3 times with PBST. Next, 100 μL of 4 μg/mL biotinylated goat anti-human TARC (R & D systems) was added to each well and incubated at 37 °C for 30 min. After five washes with PBST, the wells were filled with 100 μL of 2 μg/mL horseradish peroxidase-conjugated streptavidin (BD Biosciences, Franklin Lakes, NJ, USA) and incubated at 37 °C for 30 min. Then, the wells were washed five times with PBST, after which 100 μL TMB Microwell Peroxidase Substrate System (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA) was added to each well, and the plate was incubated at 30 °C for 15 min. The reaction was stopped by adding 100 μL 1 M phosphoric acid. The absorbance at 450 nm was measured on an iMark microplate reader (Bio-Rad Laboratories, Hercules, CA, USA).

Statistical analysis

The results obtained in the animal study were analysed using a Mann–Whitney U test. The results obtained in the cell culture study were statistically analysed using a two-tailed Student’s t-test. P-values less than 0.05 were considered to indicate a statistically significant difference.

Results

Effect of QSEtE treatment on Biostir-AD-induced skin lesions in NC/Nga mice

QSEtE was obtained from the seeds of quince with a 0.3% yield on wet weight basis. To examine the effects of QSEtE on AD-like skin lesions in vivo, NC/Nga mice were administered different doses of QSEtE prior to Biostir-AD application. At 1 week after the application of QSEtE, no observable skin irritation was identified. Repeated application of Biostir-AD macroscopically resulted in AD-like lesions on the dorsal skin of mice after 3 weeks. The average clinical severity scores for each group on day 28 were as follows: 8.2 ± 3.9 (vehicle), 2.8 ± 1.7 (0.1% QSEtE), and 0.5 ± 0.8 (1.0% QSEtE) (Fig. 2). Total clinical severity scores in QSEtE-treated groups dose-dependently decreased compared with the scores of vehicle-treated mice. In particular, small lesions of the skin were observed in the 1.0% QSEtE-treated group throughout the entire experimental period. Among the three groups, there were no noticeable adverse effects and no significant differences in body weight gain (data not shown).

Fig. 2
figure 2

Effect of QSEtE pretreatment on the development of atopic dermatitis-like skin lesions in NC/Nga mice. a Clinical skin severity score. Clinical skin severity scores of mice were measured on day 0, and every 7 days after, of the experimental period. Clinical scores are expressed as the mean ± standard deviation (n = 6 per group). *P < 0.05 and ***P < 0.001 vs. vehicle group (Mann-Whitney’s U test). b Biostir-AD-induced skin lesions in dorsal skin. Photographs were taken on the last day (day 28) of the experimental period

Full size image

AD-like symptom, such as epidermal thickening and infiltration of inflammatory cells in the dermis, were observed on day 28 of the experiment (Fig. 3a). QSEtE-treated mice showed a marked reduction in the degree of mast cell infiltration in the skin compared to that reported for the vehicle-treated mice (Fig. 3b).

Fig. 3
figure 3

Effect of QSEtE pretreatment on skin lesions in NC/Nga mice. a Hematoxylin and eosin-stained dorsal skin lesions. b Toluidine blue-stained dorsal skin lesions. The histological images were taken on the last day (day 28) of the experimental period

Full size image

Effect of QSEtE on serum total IgE levels of NC/Nga mice

The IgE levels in the serum of mice are shown in Fig. 4. Serum total IgE levels of mice in the vehicle group, 0.1% QSEtE group, and 1.0% QSEtE group were approximately 3418 ng/mL, 2108 ng/mL, and 1895 ng/mL, respectively. IgE levels in 0.1% QSEtE and 1.0% QSEtE group were significantly lower (P < 0.01) than those of the vehicle group.

Fig. 4
figure 4

Effect of QSEtE on serum total IgE levels of NC/Nga mice. Blood samples were collected on the last day (day 28) of the experimental period. Data are expressed as the mean ± standard error (n = 3). ***P < 0.001 vs. vehicle group (Student’s t-test)

Full size image

Effect of QSEtE on TARC expression in the dorsal skin of NC/Nga mice

The TARC expression level in the dorsal skin of mice is shown in Fig. 5. Topical application of QSEtE at the concentrations of 0.1 and 1.0% reduced TARC expression by approximately 41 and 47%, respectively. These reductions were significant in comparison with those observed for the vehicle mice (P < 0.01 and P < 0.001, respectively).

Fig. 5
figure 5

Effect of QSEtE treatment on TARC expression in dorsal skin of NC/Nga mice. Dorsal skin was harvested on the last day (day 28) of the experimental period. Data are expressed as the mean ± standard error (n = 3). **P < 0.01 and ***P < 0.001 vs. vehicle group (Student’s t-test)

Full size image

Effect of QSEtE treatment on TNF-α- and IFN-γ-induced TARC expression in HaCaT cells

HaCaT cells stimulated with TNF-α and IFN-γ demonstrated increased TARC expression levels compared with those reported for unstimulated cells as described previously [14]. QSEtE (456, 913, 1825, 3650 or 7300 ng/mL) suppressed TNF-α- and IFN-γ-induced TARC expression in a dose-dependent manner (Fig. 6a). Moreover, TARC protein secreted in the supernatant of cells was significantly suppressed by QSEtE at 14,600 ng/mL (P < 0.01; Fig. 6b). Under our culture conditions, no significant difference in the proliferation and viability of HaCaT cells was observed at QSEtE concentrations ≤ 40,000 ng/mL (data not shown).

Fig. 6
figure 6

Effect of QSEtE on TNF-α- and IFN-γ-induced TARC expression and production of HaCaT cells. a TARC mRNA expression in HaCaT cells treated with TNF-α and IFN-γ (each 10 ng/mL) for 6 h. The expression of mRNA was measured using quantitative reverse transcription-polymerase chain reaction. Values are expressed as the mean ± standard deviation of three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 (Student’s t-test). b TARC production in the culture supernatant of HaCaT cells treated with TNF-α and IFN-γ (each 10 ng/mL) for 24 h. Concentrations of TARC were measured using sandwich enzyme-linked immunosorbent assay. Values are expressed as the mean ± standard deviation of three independent experiments. **P < 0.01 (Student’s t-test)

Full size image

Discussion

AD often causes a disturbance of the epidermal-barrier function, resulting in dry skin and immune responses against environmental allergens [15]. Various factors are involved in the pathogenesis and development of AD. In particular, house dust mite allergens are considered to be the most common cause of AD [16]. In fact, extracts from D. farinae, a common house dust mite, cause AD-like eczematous skin lesions in NC/Nga mice [17]. In the present study, we investigated the effect of QSEtE on house dust mite-induced AD-like skin lesions in NC/Nga mice.

Throughout this study, we demonstrated that QSEtE pre-treatment dramatically reduced subsequently induced dermatitis symptoms (Figs. 2 and 3a), mast cell infiltration (Fig. 3b), and serum IgE level (Fig. 4). In addition, we showed that TARC expression decreased in skin lesions in mice (Fig. 5), and in in vitro cultures of HaCaT cells (Fig. 6).

TARC, also known as CC chemokine ligand 17, is a member of C-C chemokine family and is mainly produced by keratinocytes, dendritic cells, endothelial cells and fibroblasts [18]. Previous studies showed that TARC acts as a chemoattractant that guides Th2 cells that highly express CC chemokine receptor (CCR) 4 and CCR8 [19, 20]. Th2 cells produce chemokines, such as RANTES, a potent chemoattractant for memory-type cluster of differentiation 4 T cells, eosinophils and mast cells, which results in Th2-skewed atopic inflammation [21]. When NC/Nga mice develop AD-like lesions, TARC is overproduced by the keratinocytes in skin lesions, but not in the skin without lesions [22].

In addition, TARC is produced by keratinocytes and has been shown to accelerate inflammatory responses in the skin of human AD patients [23]. In many cases, the serum level of TARC is elevated in patients with AD, and is closely associated with the disease activity of AD [24–26]. Therefore, TARC is recognized as a therapeutic target in the treatment of allergic disorders [27, 28]. Our results suggest the involvement of the suppressive effect of QSEtE on atopic symptoms and TARC production in the skin lesions of NC/Nga mice.

As shown in Fig. 4, we also found that serum levels of IgE were significantly suppressed in the group receiving topical application of QSEtE as compared with that reported for the vehicle-treated group. Although the mechanism of IgE suppression by QSEtE remains unclear, Jung et al. [29] reported that TARC-suppressive phenolic compounds ameliorated AD symptoms accompanied by the suppression of serum IgE. In general, synthesis of IgE by B cells is stimulated by various Th2 cell-derived cytokines such as IL-4, IL-5 and IL-13 [30, 31]. Elevated IgE eventually results in the development of AD-like skin lesions by mediating mast cell degranulation. IgE-associated mast cell degranulation releases inflammatory mediators such as histamine, which increases blood vessel permeability, thus facilitating immune cell migration from the circulation to the affected tissue, resulting in aggravation of AD symptoms [32]. Therefore, we hypothesize that the suppression of TARC in lesion site by QSEtE may suppress the of mast cell recruitment and improve Th1/Th2 immune balance to downregulate IgE production, resulting in the alleviation of IgE- and mast cell-related atopic symptoms. In this study, we did not determine the components responsible for the anti-atopic effect of QSEtE. However, it should be noted that QSEtE could easily pass through the sterilizing filter easily, which was different from the property of water-soluble quince seed mucilage. Additional studies are needed to identify the primary active components of QSEtE

Conclusions

In conclusion, we showed that the topical application of QSEtE reduced the development of house dust mite allergen-induced skin lesions in NC/Nga mice. In addition, in vitro evaluations showed that QSEtE directly suppressed TARC expression and the production of keratinocytes. Although the results obtained from NC/Nga mice would be difficult to directly extrapolate to humans owing to genetic heterogeneity of humans, the ability of QSEtE to suppress TARC from keratinocytes may have a role in its effectiveness for treating AD. We believe that QSEtE could be a good candidate to protect the skin from allergen-induced Th2-type inflammation in the onset and development of AD.

Abbreviations

AD:

Atopic dermatitis

CCR:

CC chemokine receptor

GAPDH:

Glyceraldehyde-3-phosphate dehydrogenase

QSEtE:

Ethanol extract of quince seeds

TARC:

Thymus and activation-regulated chemokine

References

  1. Ganopoulos I, Merkouropoulos G, Pantazis S, Tsipouridis C, Tsaftaris A. Assessing molecular and morpho-agronomical diversity and identification of ISSR markers associated with fruit traits in quince (Cydonia oblonga). Genet Mol Res. 2011;10(4):2729–46.

    Article  CAS  PubMed  Google Scholar 

  2. Schreyen L, Dirinck P, Sandra P, Schamp N. Flavor analysis of quince. J Agric Food Chem. 1979;27(4):872–6.

    Article  CAS  Google Scholar 

  3. Smith F, Montgomery R. The chemistry of plant gums and mucilages. New York: Reinhold Publishing Corporation; 1959.

  4. Ghafourian M, Tamri P, Hemmati A. Enhancement of human skin fibroblasts proliferation as a result of treating with quince seed mucilage. Jundishapur J Nat Pharm Prod. 2015;10(1):e18820.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Tamri P, Hemmati A, Boroujerdnia MG. Wound healing properties of quince seed mucilage: in vivo evaluation in rabbit full-thickness wound model. Int J Surg. 2014;12(8):843–7.

    Article  PubMed  Google Scholar 

  6. Hemmati AA, Kalantari H, Jalali A, Rezai S, Zadeh HH. Healing effect of quince seed mucilage on T-2 toxin-induced dermal toxicity in rabbit. Exp Toxicol Pathol. 2012;64(3):181–6.

    Article  CAS  PubMed  Google Scholar 

  7. Grieve M. A Modern Herbal: the medicinal, culinary, cosmetic and economic properties, cultivation and folklore of herbs, grasses, fungi, shrubs, and trees with all their modern scientific uses. New York: Dover Publications; 1971.

    Google Scholar 

  8. Williams HC. Epidemiology of atopic dermatitis. Clin Exp Dermatol. 2000;25(7):522–9.

    Article  CAS  PubMed  Google Scholar 

  9. Coombs RRA, Gell PGH. “Clinical aspects of immunology” 2nd ed. Oxford: Blackwell Science Publication; 1968. p. 575–96.

    Google Scholar 

  10. Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, Gray PW, Matsushima K, Yoshie O. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol. 1999;11(1):81–8.

    Article  CAS  PubMed  Google Scholar 

  11. Yamamoto M, Haruna T, Yasui K, Takahashi H, Iduhara M, Takaki S, Deguchi M, Arimura A. A novel atopic dermatitis model induced by topical application with Dermatophagoides farinae extract in NC/Nga mice. Allergol Int. 2007;56(2):139–48.

    Article  PubMed  Google Scholar 

  12. Sumiyoshi K, Nakao A, Setoguchi Y, Tsuboi R, Okumura K, Ogawa H. TGF-beta/Smad signaling inhibits IFN-gamma and TNF-alpha-induced TARC (CCL17) production in HaCaT cells. J Dermatol Sci. 2003;31(1):53–8.

    Article  CAS  PubMed  Google Scholar 

  13. Kawahara T, Nakayama D, Tanaka K, Yasui H. Effect of oral administration of the IgE-suppressive wild yeast strain Saccharomyces paradoxus P01 on the development of atopic dermatitis-like symptoms in NC/Nga mice. Food Sci Technol Res. 2015;21(2):223–30.

    Article  CAS  Google Scholar 

  14. Vestergaard C, Kirstejn N, Gesser B, Mortensen JT, Matsushima K, Larsen CG. IL-10 augments the IFN-γ and TNF-α induced TARC production in HaCaT cells: a possible mechanism in the inflammatory reaction of atopic dermatitis. J Dermatol Sci. 2001;26:46–54.

    Article  CAS  PubMed  Google Scholar 

  15. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361(9352):151–60.

    Article  PubMed  Google Scholar 

  16. Lee HH, Ahn JH, Kwon AR, Lee ES, Kwak JH, Min YH. Chemical composition and antimicrobial activity of the essential oil of apricot seed. Phytother Res. 2014;28(12):1867–72.

    Article  CAS  PubMed  Google Scholar 

  17. Matsuoka H, Maki N, Yoshida S, Arai M, Wang J, Oikawa Y, Ikeda T, Hirota N, Nakagawa H, Ishii A. A mouse model of the atopic eczema/dermatitis syndrome by repeated application of a crude extract of house-dust mite Dermatophagoides farinae. Allergy. 2003;58(2):139–45.

    Article  CAS  PubMed  Google Scholar 

  18. Saeki H, Tamaki K. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. J Dermatol Sci. 2006;43(2):75–84.

    Article  CAS  PubMed  Google Scholar 

  19. Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem. 1997;272(23):15036–42.

    Article  CAS  PubMed  Google Scholar 

  20. Bernardini G, Hedrick J, Sozzani S, Luini W, Spinetti G, Weiss M, Menon S, Zlotnik A, Mantovani A, Santoni A, Napolitano M. Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor. Eur J Immunol. 1998;28(2):582–8.

    Article  CAS  PubMed  Google Scholar 

  21. Mattoli S, Ackerman V, Vittori E, Marini M. Mast cell chemotactic activity of RANTES. Biochem Biophys Res Commun. 1995;209(1):316–21.

    Article  CAS  PubMed  Google Scholar 

  22. Vestergaard C, Yoneyama H, Murai M, Nakamura K, Tamaki K, Terashima Y, Imai T, Yoshie O, Irimura T, Mizutani H, Matsushima K. Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J Clin Invest. 1999;104(8):1097–105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CG. A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA + CCR4+ lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol. 2000;115(4):640–6.

    Article  CAS  PubMed  Google Scholar 

  24. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, Torii H, Asahina A, Onai N, Matsushima K, Tamaki K. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 2001;107(3):535–41.

    Article  CAS  PubMed  Google Scholar 

  25. Horikawa T, Nakayama T, Hikita I, Yamada H, Fujisawa R, Bito T, Harada S, Fukunaga A, Chantry D, Gray PW, Morita A, Suzuki R, Tezuka T, Ichihashi M, Yoshie O. IFN-γ-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis. Int Immunol. 2002;14(7):767–73.

    Article  CAS  PubMed  Google Scholar 

  26. Kataoka Y. Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. J Dermatol. 2014;41(3):221–9.

    Article  CAS  PubMed  Google Scholar 

  27. Herz U, Bunikowski R, Renz H. Role of T cells in atopic dermatitis. New aspects on the dynamics of cytokine production and the contribution of bacterial superantigens. Int Arch Allergy Immunol. 1998;115(3):179–90.

    Article  CAS  PubMed  Google Scholar 

  28. Takeuchi H, Yamamoto Y, Kitano H, Enomoto T. Changes in thymus- and activation-regulated chemokine (TARC) associated with allergen immunotherapy in patients with perennial allergic rhinitis. J Investig Allergol Clin Immunol. 2005;15(3):172–6.

    CAS  PubMed  Google Scholar 

  29. Jung MK, Hur DY, Song SB, Park Y, Kim TS, Bang SI, Kim S, Song HK, Park H, Cho DH. Tannic acid and quercetin display a therapeutic effect in atopic dermatitis via suppression of angiogenesis and TARC expression in Nc/Nga mice. J Invest Dermatol. 2010;130(5):1459–63.

    Article  CAS  PubMed  Google Scholar 

  30. Pène J, Rousset F, Brière F, Chrétien I, Wideman J, Bonnefoy JY, De Vries JE. Interleukin 5 enhances interleukin 4-induced IgE production by normal human B cells. The role of soluble CD23 antigen. Eur J Immunol. 1988;18(6):929–35.

    Article  PubMed  Google Scholar 

  31. de Vries JE. The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol. 1998;102(2):165–9.

    Article  PubMed  Google Scholar 

  32. Krystel-Whittemore M, Dileepan KN, Wood JG. Mast cell: a multi-functional master cell. Front Immunol. 2015;6:620.

    PubMed  Google Scholar 

Download references

Acknowledgements

None.

Funding

The authors declare that they have received no funding for the research reported.

Availability of data and materials

Accession numbers and their databases have been mentioned in the manuscript.

Authors’ contributions

This study was designed and conducted by TK, YH and TI. KT and EN participated in preparation of samples and data analyses. The manuscript was prepared by TK. All authors have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval

All animal experiments were approved by the Committee for Animal Experiments of Shinshu University.

Author information

Authors and Affiliations

  1. Department of Sciences of Functional Foods, Graduate School of Agriculture, Shinshu University, 8304 Minamiminowa, Kamiina, Nagano, 399-4598, Japan

    Takeshi Kawahara, Kanako Tsutsui, Eri Nakanishi & Yasunori Hamauzu

  2. Research Center for Fungal & Microbial Dynamism, Shinshu University, 8304 Minamiminowa, Kamiina, Nagano, 399-4598, Japan

    Takeshi Kawahara

  3. Jupon International, 4-31-5 Nishikojiya, Ota-ku, Tokyo, 144-0034, Japan

    Toshifumi Inoue

Authors
  1. Takeshi Kawahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kanako Tsutsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eri Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshifumi Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasunori Hamauzu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Kawahara.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kawahara, T., Tsutsui, K., Nakanishi, E. et al. Effect of the topical application of an ethanol extract of quince seeds on the development of atopic dermatitis-like symptoms in NC/Nga mice. BMC Complement Altern Med 17, 80 (2017). https://doi.org/10.1186/s12906-017-1606-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-017-1606-6

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us